Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS).
Zalcitabine is an analogue of the nucleoside deoxycytidine which, when intracellularly converted to an active triphosphate metabolite, inhibits replication of human immunodeficiency virus (HIV). Zalcitabine is thought to act in the early phase of HIV replication by inhibiting reverse transcriptase and terminating the viral DNA chain. In vitro, zalcitabine is one of the more effective nucleoside analogues currently in clinical use for HIV infection, with 0.5 mumol/L concentrations completely inhibiting HIV replication in human T lymphocyte cell lines. In clinical trials, p24 antigen levels decreased and CD4 cell counts increased in patients with acquired immunodeficiency syndrome (AIDS) receiving zalcitabine > or = 0.03 mg/kg/day as monotherapy. Dose-dependent adverse effects that include peripheral neuropathy, stomatitis and rash, restrict long term use at higher dosages, and it is unclear whether zalcitabine monotherapy is as effective as zidovudine in extending survival in HIV-infected patients. Alternating or concomitant therapy with zalcitabine and zidovudine provides effective inhibition of viral replication and disease progression (as measured by improvements in CD4 cell counts) with lower and less toxic dosage regimens. At present, therefore, zalcitabine has a place in AIDS therapy both in combination with zidovudine, and as monotherapy for patients unable to tolerate zidovudine.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D016516:CD4-CD8 Ratio / Q000187:drug effects; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D006678:HIV / Q000187:drug effects / Q000502:physiology; D006801:Humans; D006843:Hydrocarbons, Chlorinated / Q000627:therapeutic use*; D014779:Virus Replication / Q000187:drug effects
D006843:Hydrocarbons, Chlorinated; C004671:1,1-di(4-chlorophenyl)-2,2-dichlorocyclopropane